Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer

Oncogene

Volumn 35, Issue 10, 2016, Pages 1302-1313

  Niu, J ^a   Xue, A ^b   Chi, Y ^a,b,c   Xue, J ^b,c   Wang, W ^a   Zhao, Z ^b   Fan, M ^a   Yang, C H ^a   Shao, Z M ^b,c   Pfeffer, L M ^a   Wu, J ^b,c   Wu, Z H ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MICRORNA; MICRORNA 181A; PROTEIN BAX; STAT3 PROTEIN; UNCLASSIFIED DRUG; MIRN181 MICRORNA, HUMAN; MITOGEN AND STRESS-ACTIVATED PROTEIN KINASE 1; MUTAGENIC AGENT; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CELL INVASION; CELL SURVIVAL; CHROMATIN; CHROMATIN STRUCTURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA DAMAGE; FEMALE; GENOTOXICITY; HISTONE METHYLATION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG METASTASIS; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSACTIVATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; PROTEIN TRANSPORT; SECONDARY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICRORNAS; MUTAGENS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NF-KAPPA B; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN TRANSPORT; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; STAT3 TRANSCRIPTION FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84960814022     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.189     Document Type: Article

References (49)

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-Negative Breast Cancer. N Engl J Med 2010; 363: 1938-1948.
2. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010; 7: 683-692.
3. Wu ZH, Miyamoto S. Many faces of NF-kappaB signaling induced by genotoxic stress. J Mol Med 2007; 85: 1187-1202.
4. Baldwin AS. Regulation of cell death and autophagy by IKK and NF-κB: critical mechanisms in immune function and cancer. Immunol Rev 2012; 246: 327-345.
5. Boldin MP, Baltimore D. MicroRNAs: new effectors and regulators of NF-κB. Immunol Rev 2012; 246: 205-220.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
7. Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG et al. Chromatin structure analyses identify miRNA promoters. Genes Dev 2008; 22: 3172-3183.
8. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
9. Kasinski AL, Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11: 849-864.
10. Garofalo M, Croce CM. MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat 2013; 16: 47-59.
11. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013; 12: 847-865.
12. Kato M, Paranjape T, Muller RU, Nallur S, Gillespie E, Keane K et al. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene 2009; 28: 2419-2424.
13. Chaudhry MA, Sachdeva H, Omaruddin RA. Radiation-induced micro-RNA modulation in glioblastoma cells differing in DNA-repair pathways. DNA Cell Biol 2010; 29: 553-561.
14. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-1134.
15. Zhang X, Wan G, Berger FG, He X, Lu X. The ATM Kinase Induces MicroRNA Biogenesis in the DNA Damage Response. Mol Cell 2011; 41: 371-383.
16. Niu J, Shi Y, Tan G, Yang CH, Fan M, Pfeffer LM et al. DNA damage induces NFkappaB-dependent microRNA-21 upregulation and promotes breast cancer cell invasion. J Biol Chem 2012; 287: 21783-21795.
17. Tan G, Niu J, Shi Y, Ouyang H, Wu Z-H. NF-κB-dependent microRNA-125b upregulation promotes cell survival by targeting p38a upon UV radiation. J Biol Chem 2012; 287: 33036-33047.
18. McCool KW, Miyamoto S. DNA damage-dependent NF-kappaB activation: NEMO turns nuclear signaling inside out. Immunol Rev 2012; 246: 311-326.
19. Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun 2014; 5: 2977.
20. Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A et al. Lenalidomide-mediated enhanced translation of C/EBPa-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood 2013; 121: 159-169.
21. Enerly E, Steinfeld I, Kleivi K, Leivonen S-K, Aure MR, Russnes HG et al. miRNAmRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors. PLoS ONE 2011; 6: e16915.
22. Riaz M, van Jaarsveld MT, Hollestelle A, Prager-van der Smissen WJ, Heine AA, Boersma AW et al. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res 2013; 15: R33.
23. Niu J, Shi Y, Xue J, Miao R, Huang S, Wang T et al. USP10 inhibits genotoxic NF-kappaB activation by MCPIP1-facilitated deubiquitination of NEMO. EMBO J 2013; 32: 3206-3219.
24. Sansone P, Bromberg J. Targeting the Interleukin-6/Jak/Stat pathway in human malignancies. J Clin Oncol 2012; 30: 1005-1014.
25. Yang CH, Yue J, Fan M, Pfeffer LM. IFN Induces miR-21 through a Signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res 2010; 70: 8108-8116.
26. Wakahara R, Kunimoto H, Tanino K, Kojima H, Inoue A, Shintaku H et al. Phospho-Ser727 of STAT3 regulates STAT3 activity by enhancing dephosphorylation of phospho-Tyr705 largely through TC45. Genes Cells 2012; 17: 132-145.
27. Baek Sung H. When signaling kinases meet histones and histone modifiers in the nucleus. Mol Cell 2011; 42: 274-284.
28. Gehani SS, Agrawal-Singh S, Dietrich N, Christophersen NS, Helin K, Hansen K. Polycomb group protein displacement and gene activation through MSKdependent H3K27me3S28 phosphorylation. Mol Cell 2010; 39: 886-900.
29. Lau PN, Cheung P. Histone code pathway involving H3 S28 phosphorylation and K27 acetylation activates transcription and antagonizes polycomb silencing. Proc Natl Acad Sci USA 2011; 108: 2801-2806.
30. Ouyang Y-B, Lu Y, Yue S, Giffard RG. miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. Mitochondrion 2012; 12: 213-219.
31. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr., Sjoblom T et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103: 3687-3692.
32. Györffy B, Lanczky A, Eklund A, Denkert C, Budczies J, Li Q et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123: 725-731.
33. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-524.
34. Yang J, Huang J, Dasgupta M, Sears N, Miyagi M, Wang B et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci USA 2010; 107: 21499-21504.
35. Hedrich CM, Rauen T, Apostolidis SA, Grammatikos AP, Rodriguez Rodriguez N, Ioannidis C et al. Stat3 promotes IL-10 expression in lupus T cells through transactivation and chromatin remodeling. Proc Natl Acad Sci USA 2014; 111: 13457-13462.
36. Bonnay F, Nguyen XH, Cohen-Berros E, Troxler L, Batsche E, Camonis J et al. Akirin specifies NF-κB selectivity of Drosophila innate immune response via chromatin remodeling. EMBO J 2014; 33: 2349-2362.
37. Tartey S, Matsushita K, Vandenbon A, Ori D, Imamura T, Mino T et al. Akirin2 is critical for inducing inflammatory genes by bridging IκB-ζ and the SWI/SNF complex. EMBO J 2014; 33: 2332-2348.
38. Sawicka A, Hartl D, Goiser M, Pusch O, Stocsits RR, Tamir I et al. H3S28 phosphorylation is a hallmark of the transcriptional response to cellular stress. Genome Res 2014; 24: 1808-1820.
39. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Research 2010; 70: 1793-1803.
40. Jiao X, Zhao L, Ma M, Bai X, He M, Yan Y et al. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat 2013; 139: 717-730.
41. Chen Y, Ke G, Han D, Liang S, Yang G, Wu X. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. Exp Cell Res 2014; 320: 12-20.
42. Liu M, Wang J, Huang H, Hou J, Zhang B, Wang A. miR-181a-Twist1 pathway in the chemoresistance of tongue squamous cell carcinoma. Biochem Biophys Res Commun 2013; 441: 364-370.
43. Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS ONE 2014; 9: e96228.
44. Llambi F, Moldoveanu T, Tait Stephen WG, Bouchier-Hayes L, Temirov J, McCormick Laura L et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011; 44: 517-531.
45. Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP. TGFbeta upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest 2013; 123: 150-163.
46. Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K et al. Transforming growth factor-[beta] regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011; 30: 1470-1480.
47. Ji D, Chen Z, Li M, Zhan T, Yao Y, Zhang Z et al. MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. Mol Cancer 2014; 13: 86.
48. Zhou W, Fong Miranda Y, Min Y, Somlo G, Liu L, Palomares MR et al. Cancersecreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 2014; 25: 501-515.
49. Fan M, Krutilina R, Sun J, Sethuraman A, Yang CH, Wu Z-h et al. Comprehensive analysis of MicroRNA (miRNA) targets in breast cancer cells. J Biol Chem 2013; 288: 27480-27493.